A groundbreaking approach led by a team of scientists, including Rice University chemist James Tour, has the potential to ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Can pollution cause it? What about inflammation? And how do tumors spread? Here’s what scientists are learning about this ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

The addition of high-dose IV vitamin C to standard chemotherapy nearly doubled OS for patients with advanced pancreatic ...

Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days.

With such volatility, SLXN has emerged as one of the most talked-about stocks of the day, creating a buzz in the biotechnology sector. Let’s dive into the details behind this remarkable movement and ...

A team led by UT Southwestern scientists has discovered a mechanism that promotes metastasis in pancreatic, breast, and ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...